It is made available under a CC-BY-NC-ND 4.0 International license .

Fish oil supplementation modifies the genetic potential for blood lipids

Yitang Sun¹, Tryggvi McDonald¹, Abigail Baur¹, Huifang Xu¹, Naveen Brahman Bateman¹, Ye Shen², Changwei Li³, Kaixiong Ye^{1,4,#}

¹ Department of Genetics, Franklin College of Arts and Sciences, University of Georgia, Athens,

GA, USA

² Department of Epidemiology and Biostatistics, College of Public Health, University of Georgia,

Athens, GA, USA

³ Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane

University, New Orleans, LA, USA

⁴ Institute of Bioinformatics, University of Georgia, Athens, GA, USA

[#] Corresponding author

Dr. Kaixiong Ye

Department of Genetics

University of Georgia

C220 Davison Life Sciences

120 East Green Street, Athens, GA 30602

Office: 706-542-5898

Fax: 706-542-3910

Email:

Kaixiong.Ye@uga.edu

It is made available under a CC-BY-NC-ND 4.0 International license .

1 Abstract

2

3 Background

4 Dyslipidemia is a well-known risk factor for cardiovascular disease, which has been the leading 5 cause of mortality worldwide. Although habitual intake of fish oil has been implicated in 6 offering cardioprotective effects through triglyceride reduction, the interactions of fish oil with 7 the genetic predisposition to dysregulated lipids remain elusive.

8

9 **Objectives**

We examined whether fish oil supplementation can modify the genetic potential for the
circulating levels of four lipids, including total cholesterol, low-density lipoprotein cholesterol
(LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides.

13

14 Methods

15 A total of 441,985 participants with complete genetic and phenotypic data from the UK Biobank 16 were included in our study. Polygenic scores (PGS) were calculated in participants of diverse 17 ancestries. Multivariable linear regression models were used to assess associations with 18 adjustment for relevant risk factors.

19

20 **Results**

Fish oil supplementation mitigated genetic susceptibility to elevated levels of total cholesterol, LDL-C, and triglycerides, while amplifying genetic potential for increased HDL-C among 424,090 participants of European ancestry ($P_{interaction} < 0.05$). Consistent significant findings

2

It is made available under a CC-BY-NC-ND 4.0 International license .

were obtained using PGS calculated based on multiple genome-wide association studies or alternative PGS methods. We also showed that fish oil significantly attenuated genetic predisposition to high triglycerides in African-ancestry participants.

27

28 Conclusions

29 Fish oil supplementation attenuated the genetic susceptibility to elevated blood levels of total 30 cholesterol, LDL-C, and triglycerides, while accentuating genetic potential for higher HDL-C. 31 These results suggest that fish oil may have a beneficial impact on modifying genome-wide 32 elevated genetic effects on lipid levels in the general population.

It is made available under a CC-BY-NC-ND 4.0 International license .

33 Introduction

34

Dyslipidemia is well-known to be a major risk factor for cardiovascular disease (CVD), the 35 leading cause of death globally (1). Elevated levels of total cholesterol, low-density lipoprotein 36 37 cholesterol (LDL-C), and triglyceride serve as major risk factors for increased risks of ischemic 38 events, as shown in epidemiologic and Mendelian randomization studies (2-7). Conversely, a 39 raised level of high-density lipoprotein cholesterol (HDL-C) may have protective roles against 40 CVD, autoimmune disease, and cancers (8, 9). Numerous studies have found that fish oil 41 supplementation, predominantly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). 42 exerts cardioprotective effects through the reduction of triglyceride level (10-12). However, the 43 roles of fish oil supplementation in modulating genetic susceptibility to elevated lipid levels 44 remains insufficiently investigated.

45

In addition to environmental factors, studies have highlighted the essential role of genetic factors 46 47 in dyslipidemia (13). Genetic effects have been estimated to explain more than 50% of the 48 phenotypic variance in blood lipid levels (14). The differential effect of a genotype in individuals 49 with different environmental exposures, known as gene-environment interaction, also plays a 50 crucial role in determining outcomes (15, 16). A prior genome-wide interaction study identified 51 four novel loci, whose associations with blood lipids were modified by fish oil supplementation 52 (17). Expanding the previous single-variant analysis to a genome-scale, we hypothesized that the 53 genome-wide genetic effects on blood lipid levels, captured by polygenic scores (PGS), could be 54 modified by habitual fish oil supplementation.

55

It is made available under a CC-BY-NC-ND 4.0 International license .

56 In the current study, we aimed to explore the associations between fish oil supplementation 57 status and genetic predispositions to high levels of total cholesterol, LDL-C, HDL-C, and 58 triglyceride. Large-scale genome-wide association studies (GWAS) have identified numerous 59 single nucleotide polymorphisms (SNPs) significantly associated with elevated lipid levels (18). 60 Leveraging this information and employing novel PGS approaches, we aggregated individual 61 lipid-associated SNPs into genome-scale PGS for estimating the genetic predispositions to high 62 lipids among participants in UK Biobank (UKB). Then, we examined the interaction effects 63 between fish oil supplementation and these PGS on the observed levels of blood lipids. While our primary analysis focused on participants of European (EUR) ancestry, we also investigated 64 the interactions in African (AFR), Central/South Asian (CSA), and East Asian (EAS) 65 populations. 66

It is made available under a CC-BY-NC-ND 4.0 International license .

67 Methods

68

69 Study population

70 This study was conducted using data from UKB (application number 48818), which is a 71 prospective population-based study of over 0.5 million participants aged 37-73 years at 72 recruitment from 2006 to 2010 across the United Kingdom (19). The UKB study received ethical 73 approval from the National Health Service North West Centre for Research Ethics Committee, 74 and all participants provided electronically signed consent before joining the study. Participants 75 provided information on sociodemographic, lifestyle, and medical records via questionnaires at 76 baseline. Blood samples for genotyping and biomarker measurements were also collected at 77 recruitment. Of 502.369 individuals who attended baseline assessment, we excluded 6,705 78 individuals from the analysis due to missing fish oil supplementation data, mismatched 79 information between phenotypic and genetic sex, sex chromosome aneuploidy, outliers for 80 heterogeneity and missing genotype rate, and having a high degree of genetic kinship (ten or 81 more third-degree relatives identified). Our analysis primarily focused on EUR ancestry 82 participants, as they comprised the largest ancestral group in this resource. We also conducted 83 analyses with participants of AFR, CSA, and EAS ancestries. Figure 1 presents a flowchart 84 outlining the inclusion and exclusion of participants throughout our study.

85

86 Assessment of fish oil supplementation status

The fish oil supplementation status of study participants was determined during their initial assessment center visit using a touchscreen questionnaire. Specifically, participants were asked

It is made available under a CC-BY-NC-ND 4.0 International license .

about their regular consumption of certain supplements, with those reporting fish oil intake(including cod liver oil) classified as supplementing with fish oil.

91

92 Assessment of blood lipids

93 Four baseline serum lipid parameters, including total cholesterol, LDL-C, HDL-C, and 94 triglycerides, were ascertained using standard hematological methodologies. These lipids were 95 directly quantified via a robust analytical platform, the Beckman Coulter AU5800 chemistry 96 analyzer, to ensure precision and reproducibility.

97

98 **Polygenic score calculation**

99 We computed PGS for participants of EUR, AFR, CSA, and EAS ancestries in the UKB, which 100 measures the aggregated effects of genetic variants on total cholesterol, LDL-C, HDL-C, and 101 triglycerides. In our primary discovery analysis, we used summary statistics from the largest and 102 most recent GWAS to date, called the Graham SE et al. no UKB study, which excluded UKB 103 and included up to 930,672 EUR, 92,555 AFR, and 34,135 CSA ancestry participants (20). In the 104 replication analysis, we employed two additional GWAS summary statistics to calculate PGS. 105 The first is the GWAS meta-analysis using UKB and other cohorts, which was released by 106 Graham SE et al., containing up to 1,320,016 EUR, 99,432 AFR, 40,963 CSA, and 146,492 EAS 107 ancestry participants. The second is a GWAS that included up to 187,365 EUR individuals, as 108 previously reported by Willer CJ et al. (21).

109

110 The PGS of UKB participants was calculated with the weighted method: weighted PGS = $\beta_1 \times$ 111 SNP₁ + $\beta_2 \times$ SNP₂ + ... + $\beta_n \times$ SNP_n, where SNP_n is the number of effect alleles of the nth SNP,

It is made available under a CC-BY-NC-ND 4.0 International license .

112 and the β -coefficient is the effect size of the corresponding allele, which was extracted from 113 GWAS summary statistics. Quality control for genotypic data was based on the following criteria: 114 (1) imputation quality score > 0.3, (2) minor allele frequency > 0.1%, (3) genotype missingness per individual < 5%, 4) genotype call rate < 5%, and (5) Hardy-Weinberg test P-value > 1×10^{-8} . 115 Independent significant SNPs were identified at a GWAS threshold of *P*-value $< 5 \times 10^{-8}$ with 116 linkage disequilibrium (LD) clumping ($r^2 = 0.1, 250$ kb). We also utilized the PGS β -coefficient 117 118 previously generated by Weissbrod O et al. employing the methods of PolyPred, PolyPred+, and LD-pruning + P-value thresholding (P+T) (clump $r^2 = 0.5$, 250 kb) (22). To facilitate the 119 120 comparison of effects across four blood lipids, PGS was standardized to a mean of 0 and a 121 standard deviation (SD) of 1, enabling interpretation per one SD change.

122

123 Covariates

124 A series of sociodemographic, behavioral, and genetic covariates were included in our study. 125 Age, sex, and body mass index (BMI) were obtained from baseline assessments at recruitment. 126 The 22 baseline assessment center locations were situated throughout England, Scotland, and 127 Wales. Socioeconomic status, as calculated by the Townsend deprivation index, was assigned to 128 each participant corresponding to their home postcode at recruitment. Smoking and alcohol 129 drinking status were defined as never, former, and current. Physical activity levels were 130 categorized as low, moderate, and high following the International Physical Activity 131 Questionnaire protocol. Statin use was ascertained through self-report during verbal interviews. 132 Genetic data were generated through genotyping by either the UK Biobank Axiom Array or the 133 UK BILEVE Array. Participants were divided into ancestry groups based on the multi-ancestry

It is made available under a CC-BY-NC-ND 4.0 International license .

analysis from the Pan-ancestry genetic analysis of the UK Biobank (Pan-UKBB). The top 20

ancestry principal components derived from the Pan-UKBB were employed as covariates.

136

137 Statistical analysis

138 Multivariable linear regression models were conducted to assess the modifying impacts of fish 139 oil supplementation on the genetic potential for blood lipids. Two groups of covariates were used to apply these models. In the first model, we adjusted for sex, age, age², assessment centers, 140 141 genotyping array, and the top 20 genetic principal components. The second model added 142 additional covariates, including BMI, Townsend deprivation index, smoking status, alcohol 143 status, physical activity, and statin use. We investigated the association between lipid PGS and 144 lipid levels, stratifying by fish oil intake status among 424,090 participants of EUR ancestry to 145 scrutinize the influence of fish oil supplementation on genetic predisposition for lipid levels. We 146 further examined interactions between fish oil supplementation and PGS for four lipids on lipid 147 levels by adding an interaction term between fish oil intake and lipid PGS and by incorporating 148 both fish oil supplementation status and PGS as covariates in both models. Moreover, we 149 conducted these interaction analyses using 6,577 AFR, 8,648 CSA, and 2,670 EAS ancestry participants. Serum levels of total cholesterol, LDL-C, HDL-C, and triglycerides were 150 151 standardized, and their comparable effect sizes were expressed per one SD increase in the 152 corresponding blood lipid. All analyses were conducted using R (version 4.2.1).

It is made available under a CC-BY-NC-ND 4.0 International license .

153 **Results**

154

155 Study cohorts

156 A total of 441,985 participants from the UKB with complete genetic and phenotypic data were 157 included in this study, consisting mostly of individuals of EUR ancestry and a small proportion 158 of other ancestries. We present the baseline characteristics of participants of EUR ancestry 159 according to their fish oil intake status at baseline in Table 1. After quality control, 134,720 160 (31.8%) of study participants reported habitual use of fish oil supplements, while the remaining 161 289,370 participants were grouped as non-consumers of fish oil. The majority of fish oil users 162 were women (56%), with a mean age of 59 years. Those in the fish oil intake group were more 163 likely to be older, female, current alcohol drinkers, statin users, engaging in high physical 164 activity, and having higher levels of total cholesterol, LDL-C, and HDL-C, but less likely to be 165 current smokers or have an elevated BMI or triglyceride level. Among other ancestry groups, 166 2,289 (34.8%) AFR, 1,942 (22.5%) CSA, and 845 (31.6%) EAS participants took fish oil 167 supplementation and displayed similar characteristics to the EUR participants (Supplementary 168 Table 1).

169

170 Effect modification by fish oil supplementation on genetic predisposition to elevated lipids

In general, fish oil supplementation provided protection against genetic susceptibility to elevated levels of total cholesterol, LDL-C, and triglycerides, while it amplified genetic potential for higher HDL-C level. For the primary analysis using PGS (excluded UKB, Graham SE *et al.*), there was strong evidence that fish oil supplementation modified the effect of the genetic potential for four lipids in either the partially or fully adjusted model ($P_{interaction} < 0.05$) (Figure 2

It is made available under a CC-BY-NC-ND 4.0 International license .

176 and Table 2). When we generated PGS using two other GWAS summary statistics of Graham SE 177 et al. (included UKB) and Willer CJ et al., consistently significant results were observed for the 178 four lipids (Supplementary Figure 1 and Supplementary Table 2). We also calculated PGS based 179 on the β -coefficient previously generated by Weissbrod O *et al.* employing PolyPred, which is 180 another PGS method employing functionally informed fine-mapping methods to obtain the 181 posterior association coefficients. Utilizing PGS calculated via the PolyPred and P+T methods, 182 we also discovered that fish oil supplementation significantly modified the genetic potential for 183 elevated blood lipids (Supplementary Figure 2 and Supplementary Table 2).

184

185 In the stratified analysis, fish oil supplementation significantly attenuated the genetic association 186 with total cholesterol: each 1 SD increase in PGS was associated with a 0.304 SD increase (95% CI = 0.299 - 0.309) in total cholesterol among fish oil supplement users, compared to a 0.313 SD 187 188 increase (95% CI = 0.310 - 0.317) among non-users (Figure 2 and Table 2). Similarly, for LDL-189 C, a 1 SD increment in PGS resulted in an increase of 0.323 SD (95% CI = 0.318 - 0.328) in 190 LDL-C level among fish oil users, in comparison to 0.332 SD increase (95% CI = 0.328 - 0.335) 191 for people without fish oil intake. Genetic susceptibility to high triglycerides was 0.254 (95% CI 192 = 0.248 - 0.259) in the fish oil group and 0.267 (95% CI = 0.263 - 0.270) in the group not taking 193 fish oil. Lastly, the impact of PGS was more pronounced in the fish oil group (0.234, 95% CI =194 0.229 - 0.240) for HDL-C compared to participants without fish oil intake (0.227, 95% CI = 195 0.224 - 0.231). In summary, fish oil supplementation attenuates the genetic potential for elevated 196 levels of total cholesterol, LDL-C, and triglycerides, while amplifying the genetic predisposition 197 to a high level of HDL-C.

198

It is made available under a CC-BY-NC-ND 4.0 International license .

199 Interaction effects in other ancestry groups

200 In participants of AFR ancestry from UKB, we found that fish oil supplementation was 201 consistently associated with a diminished risk of genetic susceptibility to high triglycerides 202 (Supplementary Table 3). When stratified by fish oil supplementation status, each SD increase in 203 PGS correlated to a 0.099 SD (95% CI = 0.070 - 0.128) rise in triglyceride level among fish oil 204 users, compared to a 0.150 SD (95% CI = 0.125 - 0.174) increase among those not taking fish 205 oil. However, this modification effect of fish oil supplementation was not observed in 206 participants of CSA and EAS ancestries (Supplementary Tables 4 and 5). Moreover, analyses 207 involving participants from other ancestry groups did not indicate significant interaction effects 208 on total cholesterol, LDL-C, and HDL-C. In these diverse populations, the influence of PGS on 209 lipid levels remained statistically significant even after adjusting for fish oil supplementation and 210 multiple covariates (Supplementary Table 6).

It is made available under a CC-BY-NC-ND 4.0 International license .

211 **Discussion**

212

213 In this extensive prospective study involving 424,090 participants of EUR ancestry, our results 214 indicated that fish oil supplementation could modify the genetic susceptibility to elevated levels 215 of four lipids. Our findings suggested that fish oil supplementation attenuated genetic 216 predispositions to high levels of total cholesterol, LDL-C, and triglycerides, while accentuating 217 the genetic potential for increased HDL-C level. Analyzing 6,577 AFR, 8,648 CSA, and 2,670 218 EAS ancestry participants, no consistent significant interactions were found. However, for 219 participants of AFR ancestry, our results indicated that fish oil supplementation mitigates the 220 genetic risk on increased triglycerides. Collectively, our findings supported the hypothesis that 221 genome-wide genetic effects on blood lipid levels, captured by PGS, could be modified by 222 habitual fish oil supplementation.

223

224 Although substantial studies have highlighted the effects of fish oil supplements in improving the 225 lipid profile in hyperlipidemic patients, their influence on genetic susceptibility to dyslipidemia 226 remains unclear (2, 11, 23-26). A recent dose-response meta \Box analysis of 90 randomized 227 controlled trials with 72,598 participants demonstrated that DHA \Box + \Box EPA supplementation (>2) 228 g/d) reduced triglyceride level (27). Skulas-Ray AC et al. concluded that pharmacological doses 229 of omega-3 fatty acids (>3 g/d total EPA+DHA) effectively decrease triglycerides and can be 230 safely combined with other lipid-lowering agents, particularly statins (28). The Japan EPA Lipid 231 Intervention Study, involving 14,981 hypercholesterolemia Japanese patients, found that 1.8 g/d 232 EPA in combination with a statin led to lower triglycerides compared with statin therapy alone 233 (29). In the current study of non-EUR ancestry groups, we also observed fish oil attenuates

It is made available under a CC-BY-NC-ND 4.0 International license .

234 genetic susceptibility to elevated triglycerides among participants of AFR ancestry, but no 235 significant interaction was detected among participants of CSA and EAS ancestries, which may 236 be due to insufficient sample sizes. Large-scale studies covering more representative samples 237 from diverse ancestries are needed to further validate our findings. Regarding genetic factors, 238 some studies have investigated the interactions between fish oil and lipid-related genetic variants (17, 30-33). Our findings, leveraging cumulative effects of many genetic variants across the 239 240 genome to assess individual genetic predisposition to dyslipidemia, affirmed the protective role 241 of fish oil against genetic susceptibility to dyslipidemia.

242

243 The precise mechanisms underlying the observed interactions between fish oil supplementation 244 and genetic predisposition to elevated lipid levels are not vet fully elucidated. These modifying 245 effects could potentially be attributed to the multifaceted benefits derived from fish oil 246 supplements. The putative mechanisms through which fish oil supplementation influences 247 human lipoprotein metabolism include inhibition of very low-density lipoprotein (VLDL) 248 triglyceride synthesis, decreased apoprotein B synthesis, enhancement of VLDL turnover via an 249 increased fractional catabolic rate of VLDL, depression of LDL synthesis, and reduction of 250 postprandial lipemia (34). Additionally, fish oil intake has been found to exert beneficial effects 251 on several factors implicated in cardiovascular health, including inflammatory, oxidative, 252 thrombotic, vascular, and arrhythmogenic parameters (11, 35-40). However, it is plausible that 253 other mechanisms may also be involved in this modifying effect. Future functional studies are 254 warranted to discern the underlying biological mechanisms.

255

It is made available under a CC-BY-NC-ND 4.0 International license .

256 To the best of our knowledge, this is the first study to evaluate the modifying effects of fish oil 257 supplementation on genetic susceptibility to elevated lipid levels. The major strength of our 258 study lies in the large number of participants of EUR ancestry, providing sufficient statistical 259 power to detect significant interactions. Another strength of our study is the inclusion of other 260 ancestry groups, where we confirmed that fish oil attenuated genetic susceptibility to high 261 triglycerides in the AFR population. We used various GWAS summary statistics and PGS 262 methodologies to calculate PGS and applied a fully adjusted model with a wealth of data on 263 covariates, including socioeconomic characteristics, lifestyle factors, and statin use. Notably, the 264 PGS for the primary analysis incorporated multiple SNPs from the largest and most recent 265 GWAS across different cohorts, excluding any sample overlap with the UKB, thereby 266 circumventing the potential issue of spurious candidate gene interactions (41). Population 267 structure can lead to inflated estimates of PGS prediction (41). To address this, we adjusted all 268 models for the top 20 genetic principal components to minimize potential bias. This 269 comprehensive study design ensured the robustness and consistency of our findings.

270

271 Several potential limitations should also be considered. First, the self-reported fish oil intake is 272 vulnerable to both measurement error and recall bias. Second, since fish oil supplementation 273 status was assessed only at baseline, we were unable to evaluate the effects of longitudinal 274 changes or extended duration of use. Third, our data lacked details on specific doses of fish oil 275 supplementation, and future research is needed to discern the independent roles of DHA and 276 EPA at specific doses. Fourth, UKB recruited people aged between 37 and 73 years at baseline, 277 and our findings may not be generalizable to other age groups, such as children and adolescents 278 (42). Fifth, though our study included multiple ancestries, caution is advised when extrapolating

It is made available under a CC-BY-NC-ND 4.0 International license .

our findings to non-EUR populations, and future investigations with larger sample sizes are
 necessary. Lastly, given the observational design of our study, we cannot completely rule out
 reverse causation or residual confounding.

282

283 In conclusion, our findings reveal that fish oil supplementation attenuates genetic susceptibility 284 to elevated blood levels of total cholesterol, LDL-C, and triglycerides, while accentuating 285 genetic potential for higher HDL-C. Moreover, we detected fish oil modulates genetic 286 predisposition to high triglycerides among participants of AFR ancestry. These findings suggest 287 that fish oil could serve a beneficial role in modulating genetic susceptibility to elevated lipid 288 levels in the general population. Further studies with larger sample sizes from diverse ancestry 289 and accurate dose information of fish oil supplements are warranted to corroborate and expand 290 our findings.

It is made available under a CC-BY-NC-ND 4.0 International license .

291 Acknowledgments

292	The authors' responsibilities were as follows-YS and KY: designed the study; YS: performed
293	data analysis, prepared visualizations, and wrote the original draft of the manuscript; TM, AB,
294	HX, and NBB: contributed to the data analysis; YS, YS (yeshen@uga.edu), CL, and KY:
295	provided statistical advice; YS and KY: interpreted the results; KY: critically revised the paper;
296	all authors: read and approved the final manuscript and took responsibility for the integrity of the
297	work as a whole.
298	
299	Disclosure
300	The authors declare that there is no conflict of interest.
301	
302	Funding
303	This work was funded by the University of Georgia Research Foundation and by the National
304	Institute of General Medical Sciences of the National Institutes of Health under Award Number
305	R35GM143060. The content is solely the responsibility of the authors and does not necessarily
306	represent the official views of the National Institutes of Health.
307	
308	
309	Data availability

310 UK Biobank available the Access the is via application resource to 311 (http://www.ukbiobank.ac.uk). PGS coefficients generated by Graham SE et al. are available for 312 public download http://csg.sph.umich.edu/willer/public/glgcat

It is made available under a CC-BY-NC-ND 4.0 International license .

- 313 lipids2021/results/ancestry_specific/. PGS coefficients generated by Willer CJ et al. are available
- 314 for public download at
- 315 <u>http://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST002001-</u>
- 316 <u>GCST003000/GCST002221/harmonised/</u>. PGS coefficients generated by Weissbrod O *et al.* are
- 317 available for public download at <u>https://alkesgroup.broadinstitute.org/polypred_results</u>.

318

It is made available under a CC-BY-NC-ND 4.0 International license .

References

- Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol 2020;76(25):2982-3021. doi: 10.1016/j.jacc.2020.11.010.
- Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Jr., Juliano RA, Jiao L, Granowitz C, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019;380(1):11-22. doi: 10.1056/NEJMoa1812792.
- Libby P. Triglycerides on the rise: should we swap seats on the seesaw? Eur Heart J 2015;36(13):774-6. doi: 10.1093/eurheartj/ehu500.
- Klempfner R, Erez A, Sagit BZ, Goldenberg I, Fisman E, Kopel E, Shlomo N, Israel A,
 Tenenbaum A. Elevated Triglyceride Level Is Independently Associated With Increased
 All-Cause Mortality in Patients With Established Coronary Heart Disease: Twenty-Two Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry. Circ
 Cardiovasc Qual Outcomes 2016;9(2):100-8. doi: 10.1161/CIRCOUTCOMES.115.002104.
- 5. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017;38(32):2459-72. doi: 10.1093/eurheartj/ehx144.

 Toth PP, Granowitz C, Hull M, Liassou D, Anderson A, Philip S. High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real-World Administrative Claims Analysis of Statin-Treated Patients With High Residual Cardiovascular Risk. J Am Heart Assoc 2018;7(15):e008740. doi: 10.1161/JAHA.118.008740.

10.1101/JANA.118.008/40.

- Harris WS, Ginsberg HN, Arunakul N, Shachter NS, Windsor SL, Adams M, Berglund L,
 Osmundsen K. Safety and efficacy of Omacor in severe hypertriglyceridemia. J
 Cardiovasc Risk 1997;4(5-6):385-91.
- 8. von Eckardstein A, Nordestgaard BG, Remaley AT, Catapano AL. High-density lipoprotein revisited: biological functions and clinical relevance. Eur Heart J 2023;44(16):1394-407.
 doi: 10.1093/eurheartj/ehac605.
- Manson JE, Bassuk SS, Cook NR, Lee IM, Mora S, Albert CM, Buring JE, Group VR.
 Vitamin D, Marine n-3 Fatty Acids, and Primary Prevention of Cardiovascular Disease
 Current Evidence. Circ Res 2020;126(1):112-28. doi: 10.1161/CIRCRESAHA.119.314541.
- 10. Zhang Y, Sun Y, Yu Q, Song S, Brenna JT, Shen Y, Ye K. Higher ratio of plasma omega-6/omega-3 fatty acids is associated with greater risk of all-cause, cancer, and cardiovascular mortality: a population-based cohort study in UK Biobank. medRxiv 2023:2023.01.16.23284631. doi: 10.1101/2023.01.16.23284631.
- Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, Davidson MH,
 Kastelein JJP, Koenig W, McGuire DK, et al. Effect of High-Dose Omega-3 Fatty Acids vs
 Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk:

It is made available under a CC-BY-NC-ND 4.0 International license .

The STRENGTH Randomized Clinical Trial. JAMA 2020;324(22):2268-80. doi: 10.1001/jama.2020.22258.

- 12. Grevengoed TJ, Trammell SA, Svenningsen JS, Makarov MV, Nielsen TS, Jacobsen JCB, Treebak JT, Calder PC, Migaud ME, Cravatt BF, et al. An abundant biliary metabolite derived from dietary omega-3 polyunsaturated fatty acids regulates triglycerides. J Clin Invest 2021;131(6). doi: 10.1172/JCI143861.
- Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M,
 Pirruccello JP, Ripatti S, Chasman DI, Willer CJ, et al. Biological, clinical and population
 relevance of 95 loci for blood lipids. Nature 2010;466(7307):707-13. doi:
 10.1038/nature09270.
- Liu H, Wang W, Zhang C, Xu C, Duan H, Tian X, Zhang D. Heritability and Genome-Wide Association Study of Plasma Cholesterol in Chinese Adult Twins. Front Endocrinol (Lausanne) 2018;9:677. doi: 10.3389/fendo.2018.00677.
- Corraini P, Olsen M, Pedersen L, Dekkers OM, Vandenbroucke JP. Effect modification, interaction and mediation: an overview of theoretical insights for clinical investigators. Clin Epidemiol 2017;9:331-8. doi: 10.2147/CLEP.S129728.
- Ottman R. Gene-environment interaction: definitions and study designs. Prev Med 1996;25(6):764-70. doi: 10.1006/pmed.1996.0117.
- 17. Francis M, Li C, Sun Y, Zhou J, Li X, Brenna JT, Ye K. Genome-wide association study of fish oil supplementation on lipid traits in 81,246 individuals reveals new gene-diet interaction loci. PLoS Genet 2021;17(3):e1009431. doi: 10.1371/journal.pgen.1009431.
- 18. !!! INVALID CITATION !!! (18, 19).

- Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J,
 Landray M, et al. UK biobank: an open access resource for identifying the causes of a
 wide range of complex diseases of middle and old age. PLoS Med 2015;12(3):e1001779.
 doi: 10.1371/journal.pmed.1001779.
- 20. Graham SE, Clarke SL, Wu KH, Kanoni S, Zajac GJM, Ramdas S, Surakka I, Ntalla I, Vedantam S, Winkler TW, et al. The power of genetic diversity in genome-wide association studies of lipids. Nature 2021;600(7890):675-9. doi: 10.1038/s41586-021-04064-3.
- 21. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, Ganna A, Chen J, Buchkovich ML, Mora S, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet 2013;45(11):1274-83. doi: 10.1038/ng.2797.
- Weissbrod O, Kanai M, Shi H, Gazal S, Peyrot WJ, Khera AV, Okada Y, Biobank Japan P,
 Martin AR, Finucane HK, et al. Leveraging fine-mapping and multipopulation training
 data to improve cross-population polygenic risk scores. Nat Genet 2022;54(4):450-8. doi:
 10.1038/s41588-022-01036-9.
- 23. Investigators OT, Bosch J, Gerstein HC, Dagenais GR, Diaz R, Dyal L, Jung H, Maggiono AP,
 Probstfield J, Ramachandran A, et al. n-3 fatty acids and cardiovascular outcomes in
 patients with dysglycemia. N Engl J Med 2012;367(4):309-18. doi:
 10.1056/NEJMoa1203859.
- 24. Ganda OP, Bhatt DL, Mason RP, Miller M, Boden WE. Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management. J Am Coll Cardiol 2018;72(3):330-43. doi: 10.1016/j.jacc.2018.04.061.

- 25. Abdelhamid AS, Martin N, Bridges C, Brainard JS, Wang X, Brown TJ, Hanson S, Jimoh OF, Ajabnoor SM, Deane KH, et al. Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2018;7(7):CD012345. doi: 10.1002/14651858.CD012345.pub2.
- 26. Marston NA, Giugliano RP, Im K, Silverman MG, O'Donoghue ML, Wiviott SD, Ference BA, Sabatine MS. Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. Circulation 2019;140(16):1308-17. doi: 10.1161/CIRCULATIONAHA.119.041998.
- Wang T, Zhang X, Zhou N, Shen Y, Li B, Chen BE, Li X. Association Between Omega-3
 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of
 Randomized Controlled Trials. J Am Heart Assoc 2023;12(11):e029512. doi:
 10.1161/JAHA.123.029512.
- 28. Skulas-Ray AC, Wilson PWF, Harris WS, Brinton EA, Kris-Etherton PM, Richter CK, Jacobson TA, Engler MB, Miller M, Robinson JG, et al. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. Circulation 2019;140(12):e673-e91. doi: 10.1161/CIR.0000000000000709.
- 29. Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2008;200(1):135-40. doi: 10.1016/j.atherosclerosis.2008.06.003.

- 30. Madden J, Williams CM, Calder PC, Lietz G, Miles EA, Cordell H, Mathers JC, Minihane AM. The impact of common gene variants on the response of biomarkers of cardiovascular disease (CVD) risk to increased fish oil fatty acids intakes. Annu Rev Nutr 2011;31:203-34. doi: 10.1146/annurev-nutr-010411-095239.
- 31. Ferguson JF, Phillips CM, McMonagle J, Perez-Martinez P, Shaw DI, Lovegrove JA, Helal O, Defoort C, Gjelstad IM, Drevon CA, et al. NOS3 gene polymorphisms are associated with risk markers of cardiovascular disease, and interact with omega-3 polyunsaturated fatty acids. Atherosclerosis 2010;211(2):539-44. doi:

10.1016/j.atherosclerosis.2010.03.027.

- Lindi V, Schwab U, Louheranta A, Laakso M, Vessby B, Hermansen K, Storlien L, Riccardi G, A AR, Group KS. Impact of the Pro12Ala polymorphism of the PPAR-gamma2 gene on serum triacylglycerol response to n-3 fatty acid supplementation. Mol Genet Metab 2003;79(1):52-60. doi: 10.1016/s1096-7192(03)00065-9.
- 33. Madden J, Carrero JJ, Brunner A, Dastur N, Shearman CP, Calder PC, Grimble RF. Polymorphisms in the CD36 gene modulate the ability of fish oil supplements to lower fasting plasma triacyl glycerol and raise HDL cholesterol concentrations in healthy middle-aged men. Prostaglandins Leukot Essent Fatty Acids 2008;78(6):327-35. doi: 10.1016/j.plefa.2008.04.003.
- 34. Stone NJ. Fish consumption, fish oil, lipids, and coronary heart disease. Circulation 1996;94(9):2337-40. doi: 10.1161/01.cir.94.9.2337.
- 35. Duda MK, O'Shea KM, Lei B, Barrows BR, Azimzadeh AM, McElfresh TE, Hoit BD, Kop WJ, Stanley WC. Dietary supplementation with omega-3 PUFA increases adiponectin and

attenuates ventricular remodeling and dysfunction with pressure overload. Cardiovasc Res 2007;76(2):303-10. doi: 10.1016/j.cardiores.2007.07.002.

- Lavie CJ, Milani RV, Mehra MR, Ventura HO. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol 2009;54(7):585-94. doi: 10.1016/j.jacc.2009.02.084.
- 37. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 2011;58(20):2047-67.
 doi: 10.1016/j.jacc.2011.06.063.
- 38. Tribulova N, Szeiffova Bacova B, Egan Benova T, Knezl V, Barancik M, Slezak J. Omega-3
 Index and Anti-Arrhythmic Potential of Omega-3 PUFAs. Nutrients 2017;9(11). doi:
 10.3390/nu9111191.
- 39. Stirban A, Nandrean S, Gotting C, Tamler R, Pop A, Negrean M, Gawlowski T, Stratmann
 B, Tschoepe D. Effects of n-3 fatty acids on macro- and microvascular function in
 subjects with type 2 diabetes mellitus. Am J Clin Nutr 2010;91(3):808-13. doi:
 10.3945/ajcn.2009.28374.
- 40. Lee JH, O'Keefe JH, Lavie CJ, Harris WS. Omega-3 fatty acids: cardiovascular benefits, sources and sustainability. Nat Rev Cardiol 2009;6(12):753-8. doi: 10.1038/nrcardio.2009.188.
- 41. Choi SW, Mak TS, O'Reilly PF. Tutorial: a guide to performing polygenic risk score analyses. Nat Protoc 2020;15(9):2759-72. doi: 10.1038/s41596-020-0353-1.
- 42. Frensham LJ, Bryan J, Parletta N. Influences of micronutrient and omega-3 fatty acid supplementation on cognition, learning, and behavior: methodological considerations

It is made available under a CC-BY-NC-ND 4.0 International license .

and implications for children and adolescents in developed societies. Nutr Rev

2012;70(10):594-610. doi: 10.1111/j.1753-4887.2012.00516.x.

Figure and Table captions

Main Tables

Table 1. Baseline characteristics of participants of European ancestry in the UK Biobank^a

	Fish oil intake	No fish oil intake	P-value	
	(<i>n</i> =134720)	(<i>n</i> =289370)		
Age, years (SD)	59 (7.3)	56 (8.1)	<0.001	
Sex, female (%)	75726 (56)	153758 (53)	< 0.001	
Body mass index, kg/m ² (SD)	27 (4.5)	28 (4.9)	< 0.001	
Total cholesterol, mmol/L (SD)	5.78 (1.16)	5.68 (1.14)	< 0.001	
LDL cholesterol, mmol/L (SD)	3.61 (0.88)	3.55 (0.87)	< 0.001	
HDL cholesterol, mmol/L (SD)	1.48 (0.39)	1.44 (0.38)	< 0.001	
Triglycerides, mmol/L (SD)	1.75 (1.00)	1.76 (1.04)	0.036	

-	Fish oil intake	No fish oil intake	<i>P</i> -value	
	(<i>n</i> =134720)	(<i>n</i> =289370)		
Smoking status (%)			<0.001	
Never	71756 (53)	157498 (54)		
Previous	51940 (39)	97930 (34)		
Current	10527 (8)	32968 (11)		
Alcohol status (%)			< 0.001	
Never	4075 (3)	9220 (3)		
Previous	4302 (3)	10411 (4)		
Current	126232 (94)	269500 (93)		
Physical activity (%)			< 0.001	
Low	16930 (13)	47061 (16)		
Moderate	43674 (32)	96758 (33)		
High	48761 (36)	90921 (31)		
Statin use, yes (%)	24121 (18)	45463 (16)	<0.001	

It is made available under a CC-BY-NC-ND 4.0 International license

^a Values are numbers (%) for categorical variables, and mean (SD) for continuous variables. P-values were obtained from the Chisquared test (categorical variables) or the 2-sample t-test (continuous variables). LDL, low-density lipoprotein; HDL, high-density lipoprotein. **Table 2.** Association of lipid polygenic scores with observed lipid levels stratified by the fish oil intake status in UKB participants of European ancestry using GWAS summary statistics from Graham SE *et al.* (excluded UKB)^a

	Fish oil intake			No fish oil intake			
Lipids	n	β (95% CI)	<i>P</i> -value	n	β (95% CI)	<i>P</i> -value	P _{interaction} ^b
Total cholesterol, SD							
Partially adjusted association ^c	128634	0.244 (0.239, 0.249)	$<2.0 \times 10^{-16}$	276134	0.265 (0.261, 0.268)	$<2.0 \times 10^{-16}$	9.98×10 ⁻¹²
Fully adjusted association ^d	103738	0.304 (0.299, 0.309)	$<2.0 \times 10^{-16}$	222391	0.313 (0.310, 0.317)	$<2.0 \times 10^{-16}$	3.53×10 ⁻⁴
LDL cholesterol, SD							
Partially adjusted association ^c	128393	0.262 (0.257, 0.267)	$<2.0 \times 10^{-16}$	275625	0.280 (0.277, 0.284)	$<2.0 \times 10^{-16}$	6.27×10 ⁻⁹
Fully adjusted association ^d	103538	0.323 (0.318, 0.328)	$<2.0 \times 10^{-16}$	221994	0.332 (0.328, 0.335)	$<2.0 \times 10^{-16}$	0.001
HDL cholesterol, SD							
Partially adjusted association ^c	117709	0.235 (0.230, 0.240)	$<2.0 \times 10^{-16}$	252786	0.230 (0.227, 0.234)	$<2.0 \times 10^{-16}$	0.139
Fully adjusted association ^d	94880	0.234 (0.229, 0.240)	$<2.0 \times 10^{-16}$	203514	0.227 (0.224, 0.231)	$<2.0 \times 10^{-16}$	0.025
Triglycerides, SD							
Partially adjusted association ^c	128544	0.252 (0.247, 0.257)	$<2.0 \times 10^{-16}$	275897	0.265 (0.262, 0.269)	$<2.0 \times 10^{-16}$	2.45×10 ⁻⁵
Fully adjusted association ^d	103674	0.254 (0.248, 0.259)	<2.0×10 ⁻¹⁶	222215	0.267 (0.263, 0.270)	<2.0×10 ⁻¹⁶	5.42×10 ⁻⁵

^a UKB, UK Biobank; SD, standard deviation; LDL, low-density lipoprotein; HDL, high-density lipoprotein.

 b *P*-value was obtained from the interaction term between lipid PGS and fish oil supplementation. Models were adjusted for lipids PGS, fish oil supplementation, sex, age, age², assessment centers, genotyping array, the top 20 genetic principal components, body mass index, Townsend deprivation index, smoking status, alcohol status, physical activity, and statin use.

^c Models were adjusted for sex, age, age², assessment centers, genotyping array, and the top 20 genetic principal components.

^d Models were adjusted for sex, age, age², assessment centers, genotyping array, the top 20 genetic principal components, body mass index, Townsend deprivation index, smoking status, alcohol status, physical activity, and statin use.

It is made available under a CC-BY-NC-ND 4.0 International license .

Figure and Table captions

Main Figures

Figure 1. Flowchart of the study population selection.

UKB, UK Biobank; Pan-UKBB, Pan-ancestry genetic analysis of the UK Biobank; EUR, European; AFR, African; CSA, Central/South Asian; EAS, East Asian; GWAS, genome-wide association study; PGS, polygenic scores.

Figure 2. Interaction between fish oil and genetic predisposition to elevated blood lipids using GWAS summary statistics from Graham SE *et al.* (excluded UKB).

Effect estimates and 95% confidence intervals are scaled to per 1 SD increase in PGS measured in SD units. UKB, UK Biobank; GWAS, genome-wide association study; PGS, polygenic scores; Pint, *P*-value for interaction.

Supplementary Figures

Supplementary Figure 1. Interaction between fish oil and genetic predisposition to elevated blood lipids using GWAS summary statistics from Graham SE *et al.* (included UKB) and Willer CJ *et al.*.

Effect estimates and 95% confidence intervals are scaled to per 1 SD increase in PGS measured in SD units. UKB, UK Biobank; GWAS, genome-wide association study; PGS, polygenic scores; Pint, *P*-value for interaction.

Supplementary Figure 2. Interaction between fish oil and genetic predisposition to elevated blood lipids using the PGS β -coefficient generated by Weissbrod O *et al.*, including PolyPred and P+T.

Effect estimates and 95% confidence intervals are scaled to per 1 SD increase in PGS measured in SD units. PGS, polygenic scores; Pint, *P*-value for interaction.

Supplementary Tables

Supplementary Table 1. Baseline characteristics of participants of African, Central/South Asian, and East Asian ancestries in the UK Biobank^a

^a Values are numbers (%) for categorical variables, and mean (SD) for continuous variables. LDL, low-density lipoprotein; HDL, high-density lipoprotein.

Supplementary Table 2. Association of lipid polygenic scores with observed lipid levels stratified by the fish oil intake status in participants of European ancestry^a

^a UKB, UK Biobank; SD, standard deviation; LDL, low-density lipoprotein; HDL, high-density lipoprotein.

^b*P*-value was obtained from the interaction term between lipid PGS and fish oil supplementation. Models were adjusted for lipids PGS, fish oil supplementation, sex, age, age², assessment centers, genotyping array, the top 20 genetic principal components, body mass index, Townsend deprivation index, smoking status, alcohol status, physical activity, and statin use.

It is made available under a CC-BY-NC-ND 4.0 International license .

^c Models were adjusted for sex, age, age², assessment centers, genotyping array, and the top 20 genetic principal components.

^d Models were adjusted for sex, age, age², assessment centers, genotyping array, the top 20 genetic principal components, body mass index, Townsend deprivation index, smoking status, alcohol status, physical activity, and statin use.

Supplementary Table 3. Association of lipid polygenic scores with observed lipid levels stratified by the fish oil intake status in participants of African ancestry^a

^a UKB, UK Biobank; SD, standard deviation; LDL, low-density lipoprotein; HDL, high-density lipoprotein.

^b*P*-value was obtained from the interaction term between lipid PGS and fish oil supplementation. Models were adjusted for lipids PGS, fish oil supplementation, sex, age, age², assessment centers, genotyping array, the top 20 genetic principal components, body mass index, Townsend deprivation index, smoking status, alcohol status, physical activity, and statin use.

^c Models were adjusted for sex, age, age², assessment centers, genotyping array, and the top 20 genetic principal components.

^d Models were adjusted for sex, age, age², assessment centers, genotyping array, the top 20 genetic principal components, body mass index, Townsend deprivation index, smoking status, alcohol status, physical activity, and statin use.

Supplementary Table 4. Association of lipid polygenic scores with observed lipid levels stratified by the fish oil intake status in participants of Central/South Asian ancestry^a

It is made available under a CC-BY-NC-ND 4.0 International license .

^a UKB, UK Biobank; SD, standard deviation; LDL, low-density lipoprotein; HDL, high-density lipoprotein.

^b*P*-value was obtained from the interaction term between lipid PGS and fish oil supplementation. Models were adjusted for lipids PGS, fish oil supplementation, sex, age, age², assessment centers, genotyping array, the top 20 genetic principal components, body mass index, Townsend deprivation index, smoking status, alcohol status, physical activity, and statin use.

^c Models were adjusted for sex, age, age², assessment centers, genotyping array, and the top 20 genetic principal components.

^d Models were adjusted for sex, age, age², assessment centers, genotyping array, the top 20 genetic principal components, body mass index, Townsend deprivation index, smoking status, alcohol status, physical activity, and statin use.

Supplementary Table 5. Association of lipid polygenic scores with observed lipid levels stratified by the fish oil intake status in participants of East Asian ancestry^a

^a UKB, UK Biobank; SD, standard deviation; LDL, low-density lipoprotein; HDL, high-density lipoprotein.

^b*P*-value was obtained from the interaction term between lipid PGS and fish oil supplementation. Models were adjusted for lipids PGS, fish oil supplementation, sex, age, age², assessment centers, genotyping array, the top 20 genetic principal components, body mass index, Townsend deprivation index, smoking status, alcohol status, physical activity, and statin use.

^c Models were adjusted for sex, age, age², assessment centers, genotyping array, and the top 20 genetic principal components.

It is made available under a CC-BY-NC-ND 4.0 International license .

^d Models were adjusted for sex, age, age², assessment centers, genotyping array, the top 20 genetic principal components, body mass index, Townsend deprivation index, smoking status, alcohol status, physical activity, and statin use.

Supplementary Table 6. Effects of fish oil supplementation and PGS on observed lipid levels in UKB participants of diverse ancestries^a

^a UKB, UK Biobank; SD, standard deviation; LDL, low-density lipoprotein; HDL, high-density lipoprotein; EUR, European; AFR, African; CSA, Central/South Asian; EAS, East Asian.

^b Models were adjusted for sex, age, age², assessment centers, genotyping array, and the top 20 genetic principal components.

^c Models were adjusted for sex, age, age², assessment centers, genotyping array, the top 20 genetic principal components, body mass index, Townsend deprivation index, smoking status, alcohol status, physical activity, and statin use.

It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 1



It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 2

